Marshall Wace
PBYI icon

Marshall Wace’s Puma Biotechnology PBYI Stock Holding History

Marshall Wace’s Portfolio PBYI Stock Details PBYI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-557,548
Closed -$2.96M – 3353
2025
Q3 		$2.96M Buy
557,548
+484,133
+659% +$2.05M ﹤0.01% 1423
2025
Q2 		$252K Sell
73,415
-142,998
-66% -$456K ﹤0.01% 2380
2025
Q1 		$641K Buy
216,413
+130,833
+153% +$410K ﹤0.01% 1967
2024
Q4 		$261K Buy
+85,580
New +$249K ﹤0.01% 2276
2024
Q3 		– Sell
-200,085
Closed -$652K – 2843
2024
Q2 		$652K Sell
200,085
-38,406
-16% -$169K ﹤0.01% 1868
2024
Q1 		$1.26M Sell
238,491
-110,131
-32% -$593K ﹤0.01% 1555
2023
Q4 		$1.51M Buy
348,622
+134,409
+63% +$445K ﹤0.01% 1339
2023
Q3 		$563K Sell
214,213
-10,580
-5% -$36K ﹤0.01% 1679
2023
Q2 		$794K Buy
224,793
+50,977
+29% +$159K ﹤0.01% 1821
2023
Q1 		$537K Sell
173,816
-147,441
-46% -$556K ﹤0.01% 2069
2022
Q4 		$1.36M Buy
+321,257
New +$1.11M ﹤0.01% 1938
2022
Q1 		– Sell
-396,967
Closed -$1.21M – 3853
2021
Q4 		$1.21M Buy
396,967
+373,691
+1,605% +$1.62M ﹤0.01% 2379
2021
Q3 		$163K Buy
+23,276
New +$174K ﹤0.01% 2832
2019
Q2 		– Sell
-6,788
Closed -$263K – 1721
2019
Q1 		$263K Sell
6,788
-5,008
-42% -$153K ﹤0.01% 1286
2018
Q4 		$241K Buy
+11,796
New +$354K ﹤0.01% 1253
2018
Q3 		– Sell
-4,892
Closed -$289K – 1249
2018
Q2 		$289K Buy
+4,892
New +$284K ﹤0.01% 635
2016
Q2 		– Sell
-17,700
Closed -$520K – 1118
2016
Q1 		$520K Sell
17,700
-77,265
-81% -$3.49M 0.01% 842
2015
Q4 		$7.45M Buy
+94,965
New +$7.45M 0.07% 291
2015
Q2 		– Sell
-16,513
Closed -$3.9M – 1011
2015
Q1 		$3.9M Buy
+16,513
New +$3.53M 0.05% 363
2014
Q3 		– Sell
-9,416
Closed -$621K – 996
2014
Q2 		$621K Buy
+9,416
New +$670K 0.01% 574

Other funds holding PBYI

ACA
Acorn Capital Advisors New York $366M AUM 474.6% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
OSAM
O'Shaughnessy Asset Management Stamford, Connecticut $21.7B AUM 41.93% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Marshall Wace's PBYI Position: Q4 2025 in Review

Marshall Wace sold out of Puma Biotechnology (PBYI) in Q4 2025, closing a stake of 557,548 shares — an estimated $2.96M sold.

Marshall Wace first reported a position in PBYI in Q2 2014 and held it in 20 quarters. The position peaked at $7.45M in Q4 2015. 151 funds tracked by Wall St. Rank hold PBYI as of Q4 2025.

  • Marshall Wace reported no remaining Puma Biotechnology position as of Q4 2025 after selling out during the quarter.
  • Marshall Wace sold 557,548 Puma Biotechnology shares in Q4 2025, an estimated $2.96M.
  • Marshall Wace first reported a position in Puma Biotechnology in Q2 2014 and held it in 20 quarters.
  • Marshall Wace's Puma Biotechnology position peaked at $7.45M in Q4 2015.
  • 151 funds tracked by Wall St. Rank held Puma Biotechnology as of Q4 2025.

Based on Marshall Wace's 13F filing for Q4 2025, filed 13 Feb 2026.